Get our Free Patent Expiration Newsletter

Serving hundreds of leading biopharmaceutical companies globally:

Johnson and Johnson
Boehringer Ingelheim
Federal Trade Commission
Citi
Colorcon
Farmers Insurance

Generated: September 22, 2019

DrugPatentWatch Database Preview

Details for Patent: 8,227,462

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Which drugs does patent 8,227,462 protect, and when does it expire?

Patent 8,227,462 protects PIQRAY and is included in one NDA.

This patent has forty-seven patent family members in forty-one countries.

Summary for Patent: 8,227,462
Title:Pyrrolidine-1,2-dicarboxamide derivatives
Abstract: The present invention relates to a compound of formula (I) ##STR00001## or a salt thereof, wherein the substituents are as defined in the description, to compositions and use of the compounds in the treatment of diseases ameloriated by inhibition of phosphatidylinositol 3-kinase.
Inventor(s): Fairhurst; Robin Alec (Basel, CH), Guagnano; Vito (Basel, CH), Imbach; Patricia (Kalseraugst, CH), Caravatti; Giorgio (Bottmingen, CH), Furet; Pascal (Thann, FR)
Assignee: Novartis AG (Basel, CH)
Application Number:12/556,964
Patent Claim Types:
see list of patent claims
Use; Composition; Compound;

Drugs Protected by US Patent 8,227,462

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Novartis Pharms Corp PIQRAY alpelisib TABLET;ORAL 212526-001 May 24, 2019 RX Yes No   Try a Free Trial   Try a Free Trial Y Y IN COMBINATION WITH FULVESTRANT FOR TREATMENT OF POSTMENOPAUSAL WOMEN, AND MEN, WITH HR-POSITIVE, HER-2-NEGATIVE, PIK3CA-MUTATED, ADVANCED OR METASTATIC BREAST CANCER   Try a Free Trial
Novartis Pharms Corp PIQRAY alpelisib TABLET;ORAL 212526-002 May 24, 2019 RX Yes No   Try a Free Trial   Try a Free Trial Y Y IN COMBINATION WITH FULVESTRANT FOR TREATMENT OF POSTMENOPAUSAL WOMEN, AND MEN, WITH HR-POSITIVE, HER-2-NEGATIVE, PIK3CA-MUTATED, ADVANCED OR METASTATIC BREAST CANCER   Try a Free Trial
Novartis Pharms Corp PIQRAY alpelisib TABLET;ORAL 212526-003 May 24, 2019 RX Yes Yes   Try a Free Trial   Try a Free Trial Y Y IN COMBINATION WITH FULVESTRANT FOR TREATMENT OF POSTMENOPAUSAL WOMEN, AND MEN, WITH HR-POSITIVE, HER-2-NEGATIVE, PIK3CA-MUTATED, ADVANCED OR METASTATIC BREAST CANCER   Try a Free Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 8,227,462

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
08164104Sep 10, 2008

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Argus Health
Deloitte
Express Scripts
McKesson
QuintilesIMS
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.